Navigation Links
New method proposed for determining which patients should get treatment for colorectal cancer
Date:5/16/2008

A new study being presented at the American Society of Clinical Oncology meeting in Chicago (Abstract #4020), may change treatment practice in about 25 percent of patients with colon cancer and is the basis for proposed changes to the way colorectal cancers will be staged.

This new study, using National Cancer Institute (NCI) SEER population-based statistic registries from 1992 to 2004, and phase III clinical trial data, shows that outcomes of patients with positive nodes (Stage III) in colorectal cancer interact, to a greater extent than previously thought, with how deeply the cancer penetrates the bowel wall.

Survival outcomes depend on the thickness of the primary cancer within or beyond the bowel wall in addition to whether nodes are positive or negative. A patient with a node positive thin lesion (i.e., confined to the bowel wall) has a stage III cancer with better survival outcomes than a patient with a Stage II node negative thick cancer that penetrates beyond the bowel wall. The current standard of practice for colon cancer patients is that all or most Stage III patients receive chemotherapy after surgical removal of their cancer, but Stage II patients do not routinely receive chemotherapy. In a separate National Cancer Data Base (NCDB) analysis, patients with Stage III colon cancers confined to the bowel wall who did not receive chemotherapy still had better survival than Stage II patients.

Guidelines for adjuvant therapy may need re-examination in future clinical trials as well as more research into the molecular basis for the interplay between a primary cancer's ability to penetrate the bowel wall and to spread to regional nodes.

Also, the survival of patients whose cancers invade beyond the bowel wall to involve adjacent structures or organs is worse than that of patients whose cancers merely penetrate to the surface of the bowel wall (the reverse had been thought to be true).


'/>"/>

Contact: Traci Klein
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

0

GOOD

Page: 1

Related medicine news :

1. Stanford study highlights cost-effective method of lowering heart disease risks
2. Different method of evaluating the urinary tract system reduces radiation dose
3. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
4. A classic method for modeling skin cancer is featured in Cold Spring Harbor Protocols
5. Researcher developing new method for hearing loss assessment
6. Medicare Prescription Drug Benefit, Nonprofit Hospitals, Ambulatory Surgery Centers, Statistical Methods, and Pay-For-Performance Highlighted In the Latest INQUIRY Journal
7. GPS-like technology helps pinpoint best methods for moving injured players
8. New Seminar Series from Activator Methods Teaches Doctors a Unique Approach to Improving Nations Chiropractic Care: Focus on the Patients
9. Less invasive lymph node biopsy method could spare thousands unnecessary operations
10. 454 Sequencing(TM): Science Paper Describes a Novel, Highly Efficient Method of Sequencing Ancient DNA; Sequences the Mitochondria of 10 Individual Mammoths to Prove It
11. Manchester researchers announce new methods of beating breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...s the Latest Developments in Molecular,Testing and... /PRNewswire-USNewswire/ -- The practice of,pathol...g and the promise,of personalized medicine will ch...and other imaging technologies will change the way...ogists is taking a leadership role in,making sure ...
(Date:9/5/2008)...RNewswire-USNewswire/ -- The Health Resources,and ... million in grants to,increase and improve medical... grants continue President Bush,s historic expansi...w reach more economically,vulnerable and geographi...dministrator Elizabeth M. Duke said. "In 2007, mor...
(Date:9/5/2008)...tical ,anti-cloak, could bring objects out of hidi...-- Just in case someone develops a cloak of invisi... how to uncloak the objects it hides. , Accordi...in materials underneath an invisibility cloak woul...esearchers at Shanghai Jiao Tong University in Chi...
(Date:9/5/2008)...ain to commit to develop a National AIDS,Strategy ...p. 5 /PRNewswire-USNewswire/ -- The,Republican Nat...ion of the,domestic AIDS epidemic in the United St...erseas. Neither Presidential nominee Sen. John McC... mentioned AIDS in their remarks,to Convention del...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 3
...rom constipation are more likely to get diagnosed ...ientists have little idea why this should be the c... may have some effect on the function of the gut l...re. Dr Robert Abbott, who led the research, said:...
...ts have no proven effectiveness in long-term weigh...those who adhere to them for more than a short tim...rt Associantion’s Nutrition Committee in Circulati...an Heart Association. Some of the diets increase f...
...unds commonly found in garlic may not only an effe...h they inhibit the infection appears to be similar...Researcher from the University of Toronto report t...ng of the American Society of Tropical Medicine an...
...ing the cholesterol drug simvastatin with the B vi...ther artery-disease complications by up to 90% in ...d heart arteries and low HDL (good) cholesterol sh... HDL levels, caused artery blockages to recede and...
Other Medicine News:Health News:High-protein diets may pose health risks 2Health News:Simvastatin Plus Niacin May Lower Heart Risks 2
(Date:9/4/2008)...trates potent antiviral activity and favorable saf...RIDGE, Mass., Sept. 4 /- Id...pharmaceutical company engaged,in the discovery an...viral,and other infectious diseases, today announc...y evaluating IDX899, a non-nucleoside reverse,tran...
(Date:9/3/2008)...stion Asked. Wrong Children Studied. Wrong,Conclus...ewswire/ -- A Centers for Disease,Control and Prev...no link,between the MMR vaccine and autism. The Na...es nothing to dispel the growing public concern ov...questions concerning design,and methodology., For...
(Date:9/3/2008)...s National Vascular Disease Awareness Month, CHAR...n Pharmaceuticals,LLC, a clinical-stage drug-devel...reatment of unmet medical needs, announced today t...I clinical trial of its lead drug,candidate trans ...T00725881,on the clinicaltrials.gov Website, is in...
(Date:9/3/2008)...ny to Discuss Phase 3 Plans with FDA, PRINCETON, ...Inc.,announced today that it successfully complet...he company,s new, innovative low-dose, once-weekly... by its internal product,code AG-200-15. The Phase...,primary endpoint of ovulation suppression, cycle ...
Breaking Medicine Technology:Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 2Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 3Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 4CDC Misses Target With Flawed MMR/Autism Study 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4Factor key to severity of community associated methicillin resistant staph infections identified 6042 1Factor key to severity of community associated methicillin resistant staph infections identified 6042 2Factor key to severity of community associated methicillin resistant staph infections identified 6042 3Life threatening gene defect located by UT Houston researchers 1176 1Life threatening gene defect located by UT Houston researchers 1176 2Life threatening gene defect located by UT Houston researchers 1176 3Life threatening gene defect located by UT Houston researchers 1176 4Research suggests targeted treatment strategies for lupus 6037 1Research suggests targeted treatment strategies for lupus 6037 2Human clones 3A New U N analysis lays out worlds choices 1174 1Human clones 3A New U N analysis lays out worlds choices 1174 2Human clones 3A New U N analysis lays out worlds choices 1174 3Human clones 3A New U N analysis lays out worlds choices 1174 4
...ate breaking data,presented at the American Diabet...ns showed that, when used investigationally as,ini...tion with,metformin provided significant glycemic ...54 weeks in patients with type 2,diabetes. Additio...d also showed that JANUVIA significantly improved ...
...cant Clinical Results for,SB-509 in Development fo...22, 2007 /PRNewswire-FirstCall/ -- Sangamo,BioScie...ouraging,Phase 1 clinical data from its ZFP Therap...of the American Diabetes Association,(ADA). As dis...,Neurologic Exam and Nerve Conduction Velocities i...
Other Medicine Technology:Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 2Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 3Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 4Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 5Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 6Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 7Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 8Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 9Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 10Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 11Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 12Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 13Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 14Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 15Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 16Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 17Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 18Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 19Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 20Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 21Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 22Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 23Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 24Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 25Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 26Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 27Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 28Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 29Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 30Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 31Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 32Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 2Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 3Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 4Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 5
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
Medicine Products: